Why Women’s Pain Can Persist Beyond Visible Disease

Women’s persistent pain is often assessed through what clinicians can see or measure: the number and location of endometriosis lesions, inflammatory markers, imaging, or signs of joint damage. Two recent publications reinforce why this approach can be incomplete. Symptom intensity does not always rise and fall with visible disease activity.

Research into endometriosis has identified molecular differences between painful and asymptomatic lesions, while a review of rheumatoid arthritis describes how pain and fatigue may continue after inflammation improves. These conditions are distinct, but together they support a clinically important principle: pain is a biological output shaped by more than disease extent alone.

That does not make pain unexplained or psychological. It means inflammation, neural signalling, sleep, mood, metabolic health and previous pain exposure can interact, sometimes sustaining symptoms after the original trigger has changed.

Women’s persistent pain may not match disease extent

Endometriosis is defined by tissue similar to the uterine lining growing outside the uterus. Its staging describes anatomical findings, not the severity of pain. Someone with relatively limited visible disease may experience disabling pelvic pain, while more extensive disease can be found in someone without symptoms.

A 2026 study by Mamillapalli and colleagues in Molecular Human Reproduction examined whether gene activity could help account for this mismatch. The researchers performed RNA sequencing on 27 stored peritoneal biopsy samples from nine symptomatic and ten asymptomatic participants. They identified 890 genes with different expression patterns between the two groups.

Several of the strongest signals involved inflammatory pathways, cell adhesion and neuromodulation. Seven of the 22 enriched biological pathways were related to immune function. The findings suggest that the molecular character of a lesion, including how it communicates with immune and nervous systems, may matter more for pain than lesion quantity alone.

This was a small, observational tissue study. It can identify associations but cannot show that the gene-expression differences caused pain. Stored biopsy material and a limited participant group also restrict how broadly the results can be applied. The work does not yet provide a diagnostic blood test or establish a new treatment. Its value lies in offering a plausible biological explanation for a familiar clinical pattern.

Inflammation is one contributor, not a complete pain measure

A separate 2026 review by Gunkl-Tóth and colleagues in Nature Reviews Rheumatology considered difficult-to-treat rheumatoid arthritis. Unlike a randomised trial, a review interprets an existing evidence base rather than testing one intervention in a new participant group.

Rheumatoid arthritis is an autoimmune inflammatory condition. Medication can reduce inflammation and protect joints, yet pain and fatigue may remain. The review highlights depression, poor sleep, obesity, smoking and chronic pain among factors that may sustain symptoms even when inflammatory disease activity has improved.

The distinction matters because persistent symptoms can be mistaken for continuing immune activity. Escalating immune-suppressing medication may be appropriate when inflammation remains active, but it may offer less benefit when sleep disruption, altered pain processing, deconditioning or another condition is contributing more heavily. Clinical assessment has to separate ongoing tissue inflammation from the broader mechanisms generating symptoms.

Endometriosis raises a parallel issue. Surgery and hormonal treatment can address lesions or suppress hormonal stimulation, but lesion burden is not a complete proxy for symptom burden. Persistent pelvic pain can also involve muscle guarding, pelvic-floor dysfunction, nerve sensitisation, painful bladder or bowel symptoms, and disrupted sleep. The relative contribution of each factor differs between individuals and can change over time.

Sleep and mood belong in biological pain assessment

Sleep and mood are sometimes treated as secondary consequences of pain. The relationship is often bidirectional. Pain fragments sleep, while insufficient or irregular sleep can lower pain thresholds and impair emotional regulation. Low mood can amplify fatigue and reduce function, while persistent pain itself increases the risk of depression and anxiety.

Recognising these connections should not displace investigation of physical disease. New, severe or changing pelvic pain still warrants assessment, as do symptoms such as fainting, fever, heavy bleeding, blood in urine or stool, unexplained weight change, or possible pregnancy. The point is not to replace gynaecological or rheumatological care with sleep advice. It is to avoid treating sleep, mood and fatigue as irrelevant when they may be part of the mechanism maintaining pain.

Pain patterns may also vary with the menstrual cycle. Hormonal shifts can coincide with changes in pelvic pain, migraine, bowel symptoms, sleep and perceived recovery. For those in the menopause transition, fluctuating hormones may overlap with poorer sleep, musculoskeletal discomfort and altered bleeding. A perimenopause symptom tracker can help distinguish repeated timing from isolated bad days, although tracking cannot determine the cause by itself.

Better care requires patterns, not a single pain score

A pain rating captures intensity at one moment, but not timing, duration, location, triggers or functional impact. A more informative record connects pain with bleeding, cycle phase, bowel and bladder symptoms, sleep quality, energy, mood, movement and medication use. It may show that symptoms cluster before menstruation, follow poor sleep, improve after treatment, or persist independently of either cycle timing or measured inflammation.

These observations are not proof of causation. They are structured information that can support clinical conversations and make treatment response easier to judge. They can also reveal when a presumed relationship does not hold. If pain repeatedly remains high despite better sleep, for example, that finding is useful rather than a failure of tracking.

The emerging research does not support one universal explanation for women’s persistent pain. It supports a layered model in which tissue disease, immune signalling, nerves, sleep, mood and behaviour may carry different weight at different times. That model is more complex than equating pain with visible pathology, but it is also more consistent with what many patients experience.

Pain, sleep quality, cycle symptoms and energy become readable as a connected pattern only when logged consistently over weeks. This is the kind of pattern Tulsy is built to surface through energy tracking over time.

Sources: Medical Xpress, ScienceDaily.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.